Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Surgery is the standard treatment for renal cell carcinoma (RCC).
• Some patients are ineligible for or decline surgery, necessitating alternative treatments.
• Conventional radiotherapy is often ineffective for RCC due to tumor radioresistance and toxicity.

Purpose of the Study:

• To evaluate the potential of Stereotactic Body Radiotherapy (SBRT) as an alternative treatment for renal cell carcinoma (RCC).
• To explore how SBRT can overcome the radioresistance of RCC cells.
• To assess the role of SBRT, potentially combined with immunotherapy, in managing primary and oligometastatic RCC.

Main Methods:

• Utilizing SBRT, a non-invasive radiotherapy technique delivering highly conformal doses.
• Employing image-guided techniques for precise radiation delivery.
• Investigating the impact of higher doses per fraction to increase the biological effective dose.

Main Results:

• SBRT demonstrates remarkable local control rates for primary tumors and metastases in various locations.
• SBRT is associated with low morbidity due to precise dose delivery.
• Evidence suggests higher doses per fraction can overcome RCC radioresistance.

Conclusions:

• SBRT presents a viable, non-invasive ablative treatment for RCC.
• SBRT, especially with higher doses per fraction, can overcome tumor radioresistance.
• SBRT and its combination with emerging immunotherapies hold significant potential for treating primary and oligometastatic RCC.